Alpha1-proteinase inhibitor (Human, Grifols)

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameAlpha1-proteinase inhibitor (Human, Grifols)
Drug Alias NameAlpha-1-antitrypsin IV - GrifolsAlpha-1 proteinase-inhibitor-modified process - GrifolsAlpha-1-protease-inhibitor-modified process-GrifolsAlpha1-PIAlpha-1 MP-Grifols +[10] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAlpha-1-antiproteinase replacements
TargetsAlpha-1-antiproteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary EmphysemaPulmonary Disease, Chronic Obstructive +[6] 
Global Approved Indicationsalpha 1-Antitrypsin Deficiency
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1987/12/02
Country/TerritoryCanadaUnited StatesSweden +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGrifols SaBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Irccs Policlinico San MatteoGrifols Therapeutics LlcMedical University Of South Carolina +[4] 
Inactive CompaniesGrifols Japan Kk
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary EmphysemaPulmonary Disease, Chronic Obstructive +[5] 
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeB02AB02
Related LinksWikipedia